69 related articles for article (PubMed ID: 25515669)
1. Pharmacodynamic studies of nitrofurantoin against common uropathogens.
Komp Lindgren P; Klockars O; Malmberg C; Cars O
J Antimicrob Chemother; 2015 Apr; 70(4):1076-82. PubMed ID: 25515669
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic evaluation of nitrofurantoin against Escherichia coli in a murine urinary tract infection model.
Maaland MG; Jakobsen L; Guardabassi L; Frimodt-Møller N
APMIS; 2024 Jul; 132(7):492-498. PubMed ID: 38558445
[TBL] [Abstract][Full Text] [Related]
3. Urinary concentrations and antibacterial activities of nitroxoline at 250 milligrams versus trimethoprim at 200 milligrams against uropathogens in healthy volunteers.
Wagenlehner FM; Münch F; Pilatz A; Bärmann B; Weidner W; Wagenlehner CM; Straubinger M; Blenk H; Pfister W; Kresken M; Naber KG
Antimicrob Agents Chemother; 2014; 58(2):713-21. PubMed ID: 24217699
[TBL] [Abstract][Full Text] [Related]
4. Urinary Tract Infection among Renal Transplant Recipients in Yemen.
Gondos AS; Al-Moyed KA; Al-Robasi AB; Al-Shamahy HA; Alyousefi NA
PLoS One; 2015; 10(12):e0144266. PubMed ID: 26657128
[TBL] [Abstract][Full Text] [Related]
5. Intermethod comparability analyses of gepotidacin antimicrobial susceptibility tests using a large collection of globally collected Escherichia coli and Staphylococcus saprophyticus clinical isolates.
Arends SJR; Butler D; Scangarella-Oman N; Castanheira M; Mendes R
Diagn Microbiol Infect Dis; 2024 Mar; 108(3):116181. PubMed ID: 38215519
[TBL] [Abstract][Full Text] [Related]
6. IS
Wan Y; Sabnis A; Mumin Z; Potterill I; Jauneikaite E; Brown CS; Ellington MJ; Edwards A; Sriskandan S
Microb Genom; 2023 Sep; 9(9):. PubMed ID: 37672334
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/Pharmacodynamic Relationships of Tulathromycin Against
Yao L; Yang L; Ling Y; Wei Y; Shen X; Ding H
Front Vet Sci; 2022; 9():822432. PubMed ID: 35419449
[TBL] [Abstract][Full Text] [Related]
8. Improving nitrofurantoin resistance prediction in
Dulyayangkul P; Sealey JE; Lee WWY; Satapoomin N; Reding C; Heesom KJ; Williams PB; Avison MB
Antimicrob Agents Chemother; 2024 May; ():e0024224. PubMed ID: 38767379
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics of nitrofurantoin and its related bioavailability.
Conklin JD
Antibiot Chemother (1971); 1978; 25():233-52. PubMed ID: 352255
[TBL] [Abstract][Full Text] [Related]
10. Nitrofurantoin: mechanism of action and implications for resistance development in common uropathogens.
McOsker CC; Fitzpatrick PM
J Antimicrob Chemother; 1994 May; 33 Suppl A():23-30. PubMed ID: 7928834
[TBL] [Abstract][Full Text] [Related]
11. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials.
Huttner A; Verhaegh EM; Harbarth S; Muller AE; Theuretzbacher U; Mouton JW
J Antimicrob Chemother; 2015 Sep; 70(9):2456-64. PubMed ID: 26066581
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics and differential activity of nitrofurantoin against ESBL-positive pathogens involved in urinary tract infections.
Fransen F; Melchers MJ; Meletiadis J; Mouton JW
J Antimicrob Chemother; 2016 Oct; 71(10):2883-9. PubMed ID: 27278898
[TBL] [Abstract][Full Text] [Related]
13. Updated Nitrofurantoin Recommendations in the Elderly: A Closer Look at the Evidence.
Hoang P; Salbu RL
Consult Pharm; 2016 Jul; 31(7):381-4. PubMed ID: 27412314
[TBL] [Abstract][Full Text] [Related]
14. Nitrofurantoin's efficacy and safety as prophylaxis for urinary tract infections: a systematic review of the literature and meta-analysis of controlled trials.
Muller AE; Verhaegh EM; Harbarth S; Mouton JW; Huttner A
Clin Microbiol Infect; 2017 Jun; 23(6):355-362. PubMed ID: 27542332
[TBL] [Abstract][Full Text] [Related]
15. Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota.
Stewardson AJ; Gaïa N; François P; Malhotra-Kumar S; Delémont C; Martinez de Tejada B; Schrenzel J; Harbarth S; Lazarevic V;
Clin Microbiol Infect; 2015 Apr; 21(4):344.e1-11. PubMed ID: 25658522
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of nitrofurantoin at different pH levels against pathogens involved in urinary tract infections.
Fransen F; Melchers MJB; Lagarde CMC; Meletiadis J; Mouton JW
J Antimicrob Chemother; 2017 Dec; 72(12):3366-3373. PubMed ID: 28961900
[TBL] [Abstract][Full Text] [Related]
17. Drug therapy reviews: nitrofurantoin.
Gleckman R; Alvarez S; Joubert DW
Am J Hosp Pharm; 1979 Mar; 36(3):342-51. PubMed ID: 369367
[TBL] [Abstract][Full Text] [Related]
18. Dose- and time-dependent kinetics of the renal excretion of nitrofurantoin in the rabbit.
Watari N; Aizawa K; Kaneniwa N
J Pharm Sci; 1985 Feb; 74(2):165-70. PubMed ID: 3989686
[TBL] [Abstract][Full Text] [Related]
19. Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities.
Saltoglu N; Karali R; Yemisen M; Ozaras R; Balkan II; Mete B; Tabak F; Mert A; Hondur N; Ozturk R
Int J Clin Pract; 2015 Jul; 69(7):766-70. PubMed ID: 25683907
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
